The study of peptide-targeted radionuclide therapy (PTRT) using 177Lu-FAP-2286 evaluated the efficacy of 177Lu-FAP-2286 in patients with different tumors (advanced sarcoma (Banihashemian et al., 2024), advanced pancreatic, breast, rectal, or ovarian adenocarcinoma (Baum et al., 2022)), These patients experienced a reduction in primary tumor volume and pain relief after treatment, improving the quality of life for late-stage cancer patients, with acceptable side effects. This evidence concerns the gene FAP and ovarian adenocarcinoma.